Trial Profile
A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2024
Price :
$35
*
At a glance
- Drugs Folitixorin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms AGENT
- Sponsors Isofol Medical
- 19 Mar 2024 According to an Isofol Medical BA media release, company's collaboration partner, Solasia, has confirmed its continued strong commitment in development of arfolitixorin. Isofol is presenting its strategy and a clinical development plan for the continued development of its drug candidate arfolitixorin arfolitixorin in an Investor meeting on Mar 19, 2024.
- 01 Sep 2023 Status changed from discontinued to completed.
- 04 Jul 2023 Results presented in the Isofol Medical AB Media Release.